INTRODUCTION

Rapid developments in genomic technologies now mean that it is possible to screen newborn babies for larger numbers of conditions simultaneously than ever before. The development of tandem mass spectrometry, and the declining cost and increasing efficacy of whole genome/exome sequencing using technologies such as CRISPR-Cas9 now mean that high output mass screens are on the horizon, prompting renewed interest in the potential population health and societal benefits of population-based genomic screens.1–4 By conducting untargeted genome/exome sequencing, whole panels of genetic conditions can now be screened for from a single blood sample, as well as child’s propensity to future diseases, and even their potential reactions to certain medicines and drugs. As such, direct-to-consumer private genetics companies are already capitalizing on the value of this information to new parents by offering expansive newborn screens for a nominal fee.

Haemophilia is a potential candidate condition for newborn screening being expanded to the general population, who have no known...
family history of the condition. Affecting one in every 5000 male newborns worldwide (haemophilia A) and 1 in 30 000 male newborns (haemophilia B), it is the most severe form of X-linked inherited bleeding disorder. Moreover, as the most serious type of bleed for those with haemophilia (intracranial haemorrhage) is most likely to occur during the neonatal period, and with about half of these babies having no family history of a bleeding disorder, newborn screening for the condition can also be justified on the grounds of protecting the health of both the infant, but also the mother who may have some bleeding symptoms.5

Given the perceived disease burden associated with haemophilia, however, research into population screening has previously generally focused attention on the prenatal or preconception period rather than the newborn period.6 However, with the advent of new treatments, particularly early prophylactic treatment that uses recombinant clotting factors, means that the disease burden of haemophilia is slowly evolving, altering the landscape of genetic screening.7 Indeed, the frequently observed contrast between the experiences of younger generations growing up with haemophilia and those of older generation haemophiliacs—many of whom were exposed to blood-borne viruses such as Hepatitis B/C and HIV through contaminated blood in the 1970s and 1980s—suggests that an exploration of current attitudes towards screening for haemophilia amongst the affected community is now particularly timely.8,9

Whilst the acceptability of newborn screens to (expectant) parents is a topic that has been widely explored in relation to a range of different conditions,10-12 and is a key component in the assessment of screening programmes conducted by the UK National Screening Committee, the views of affected families and adults have been less extensively researched.10,12-14 This omission is striking given that the “hands on” direct experience possessed by these families uniquely positions them to consider what an early screen would have meant for them.10 Furthermore, screening has impacts for affected families that go beyond those anticipated for the general population. These include the social implications (for example, stigmatization) that come along with a shift in the “public profile” of the condition,15 but also a potential decrease in the condition’s prevalence (as has already been observed in relation to Cystic Fibrosis since the introduction of newborn screening16), with associated implications for how the condition is prioritized in the context of the allocation of public funding for research into treatments.17

To address this identified gap in the literature, this study presents data on attitudes towards newborn genetic screening amongst people living with haemophilia A and/or B, either through having the condition themselves, or having affected relatives. By drawing on a national UK survey of families living with haemophilia, this paper contributes to an emerging area of the literature that considers the social and ethical of dimensions of screening practices from the vantage point of those already living with the disease.10,12-14,16

2 MATERIALS AND METHODS

This study reports on quantitative data that formed part of a larger exploratory sequential mixed methods study on attitudes to different types of screening programme across families living with various genetic conditions.12,18,19

Through the use of an advertisement in the newsletter of the UK Haemophilia Society, 22 adults with haemophilia and family members of people with haemophilia were recruited to participate in qualitative interviews that took place between April 2017 and March 2018. Seventeen interviews were conducted by telephone, and four interviews were conducted in person. The interview participants varied in terms of their ages, backgrounds and experiences with haemophilia as well co-morbidities (associated with contaminated blood). The final sample included eight males with haemophilia and fifteen female relatives. The interviews explored participants’ experiences with haemophilia, their views on the condition’s impact and their experiences of, and attitudes towards, reproductive genetic technologies. A thematic analysis was carried out on the qualitative interviews, and a survey, the Haemophilia Screening Survey (UK), directly developed from this analysis in order to measure both the significance and generalizability of the expressed ideas. The core themes were used to delineate the key domains of the survey, and, where possible, verbatim data extracts from interview participants were used to create attitude statement questions, accompanied by a likert scale. Demographic questions were replicated, or appear as modified versions of those included in the 2011 UK Census survey. Ethical approval for the survey was granted by the Biomedical and Scientific Research Ethics Committee in November 2017.

Survey data collection took place between January and June 2018. Participants were invited to complete it if they either had haemophilia A or B themselves or had the condition in their family. No restrictions were placed on the nature of the familial relationship, so step, adopted and fostered family members were all included.

A paper version of the survey was initially mailed to the 3000 households affected by haemophilia that were known to the Haemophilia Society UK, and an online version was made available and distributed through the Haemophilia Society’s online networks. The link was also disseminated through the social networks associated with the research project. Participants were encouraged to distribute the survey to relevant family/friends. Postal survey returns were all processed using data scanning technology to reduce human error.

The attitudes of family members and adults with haemophilia (Awh) towards newborn genetic screening (NGS) were compared to determine whether there were any statistical differences using a chi-squared analysis (Graphpad Prism software, v6).

3 RESULTS

3.1 Demographic data

In total, 327 people returned either an online (33/327) or postal survey (294/327). Of these, 148/327 (45%) were family members and 179/327 (55%) were Awh (Table 1); 173/327 (53%) participants were male (Table 1), including 21/148 (14%) family members and 152/179
also believed than an early screen could extend life expectancy and
difficulties associated with a later diagnosis (Table 2). Participants
would lead to better support, would allow parents to make informed
decisions about future pregnancies and would spare parents the
half the sample agreed that newborn screening would stop families
and children enjoying life whilst they were still symptom-free and
most disagreed with the idea that receipt of a serious diagnosis early
in life would interfere with parent-child bonding (Table 2).

Interestingly, no significant differences in support for NGS were
observed between those participants who came from families with
multiple (>2) affected members as compared to those families who
had only one or two members with haemophilia (Table 3).

74/327 (23%) responders did not support NGS: 27/148 (18%)
families and 47/179 (26%) AwH (Table 4). Sub-analysis of these re-
sponders highlights that in general they did not believe introducing
NGS would extend life expectancy or increase enrolment on clinical
trial. However, although this 23% of responders did not personally
support NGS introduction, they did not believe NGS would reduce
presymptomatic quality of life, interfere with the parent-child bond-
ning process, make the diagnosis easier to accept for the parents or
believe that it is unethical to screen newborn babies for diseases that
cannot be treated (Table 4).

4 | DISCUSSION

This study, to the best of our knowledge, is the first to explore atti-
dudes towards newborn screening amongst families and AwH. It has
revealed that most adults with, and families affected by, haemophilia
are in favour of newborn screening for the condition. With the in-
creasing use of whole genome sequencing techniques for screening
purposes, the introduction of newborn screening for conditions such
as haemophilia could mark the advent of a new era in the manage-
ment of the condition, including the possibility of using new non-fac-
tor drugs on these patients with very early diagnoses. Indeed, even
the 23% of participants who did not support newborn screening in
this study did so not because they necessarily held negative beliefs
about newborn screening (for example, that it may affect parent/child
bonding or extend the illness into the presymptomatic period) but rather
because they were unconvinced that newborn screening would confer the particular advantages cited by screening support-
ers. As such, this study did not uncover overtly negative views about
this type of screening programme.

There were some differences, however, in responses between
AwH, who are mostly male, and responding family members, who
are mostly female, with female relatives more likely to support NGS
than affected males; although these differences are not significant,
they are approaching significance \( (P = 0.08) \). It is possible that this difference highlights the scepticism on the part of AwH regarding any tangible differences that NGS would have made to their own lives, particularly as none of them had benefitted from the early interventions offered to boys with haemophilia today, such as the commencement of prophylaxis. Indeed, many had, in fact, developed
other serious co-morbidities during the course of their treatment, such as Hepatitis B/C or HIV, which may have also influenced their perceptions of medical interventions.

The female relatives of AwH, however, viewed NGS from an entirely different vantage point. While not having experienced haemophilia directly themselves, the female relatives were nevertheless more heavily implicated, both socially as mothers, but also physically, as carriers, in their reproductive outcomes than their male counterparts, which may have affected their perceptions of their responsibilities with regards to their family’s health. It is also possible that such family members may also have a more clear memory of a diagnostic odyssey, associated with later diagnosis, and may thus more clearly be able to envisage the benefits of early identification for boys with haemophilia. We found similar differences between family members and AwH in our work on attitudes to preconception and prenatal screening for haemophilia.

In spite of these differences between AwH and family members, however, support for NGS was nevertheless high. These findings, when interpreted alongside the qualitative data, suggest that the participants do not view haemophilia (even in its most severe form) to be a condition that justifies selective reproduction through preconception or prenatal screening programmes. Rather, our data suggest that participants perceived haemophilia as a “liveable” condition, and emphasized the importance of early identification (even if severity is initially unknown) in order to minimize the time to diagnosis and treatment, as well as to reduce the risks of intracranial bleeds and joint damage that can be associated with untreated haemophilia.

These findings are in line with our previous work assessing support for prenatal screening for haemophilia, which found that affected adults and their family members in support of this form of screening do so not because they believe that selective pregnancy termination is an essential option, but rather because they believe that prenatal screening can provide vital information to prepare for the birth of a haemophiliac child, and also to protect the carrier mother.

However, in spite of this scepticism around the reproductive value of screening for haemophilia, there was nevertheless support for the idea that NGS could be used by the parents of already affected children, to inform decisions about their future pregnancies.

This finding is noteworthy as it suggests that the reproductive decisions and attitudes of already affected families are viewed differently by the haemophilia community than those made by the general population, highlighting the positive way that “experiential knowledge” and insight are valued in the appraisal of future affected lives. Indeed, the families and adults who participated in this survey had direct—and often extensive—knowledge of life with haemophilia, with 136/327 participants (42%) (Table 3) of the sample having more than two people in their family living with haemophilia—a much higher rate of inter-family recurrence than has been noted by studies of screening attitudes within families affected by other genetic conditions.

Overall, therefore, this study highlights the rich and complex insights that families living with genetic disorders bring to debates around expansive screening programmes. It is critical that any screening programme for haemophilia has an infrastructure that is able to capture and accurately reflect the reality of life with the condition, as this is likely to be different to the perceptions of haemophilia within the general public. The inclusion of families and AwH into screening policy debates is a key mechanism by which this change can occur.

### 4.1 Further research/Policy implications

This study underscores the importance of consulting affected families when evaluating and implementing genetic screening programmes. Indeed, these groups have much to offer an understanding of the realities of genetic impairment, a form of knowledge that will only become more significant as genomic medicine expands and decisions will need to be made regarding which conditions should be included on genetic screening panels, and which should not. Indeed, further research could usefully explore the knowledge and views of the general public towards screening for haemophilia in order to identify differences and similarities in their perceptions of the condition, as well as to inform and facilitate the development of mechanisms of decision support as reproductive decisions become invariably more complex for the whole of society.

### 4.2 Strengths and weaknesses

Recruiting through a support group, and not clinics, may have imposed sample bias to the analysis as support groups are more likely to attract people experiencing difficulty, and those who value particular forms of support. Indeed, it is noteworthy that a high proportion of women with haemophilia (15%) participated in the study, which might be explained by the methods of recruitment, given that support groups are disproportionately accessed by women. Moreover, due to confidentiality and data protection requirements, no identifiable information was asked of participants. Whilst this may have aided recruitment, there was no means by which to prevent a participant from completing multiple surveys. In spite of these weaknesses, however, the final sample was nevertheless diverse.

### Table 3: Support for NGS among families associated with increased numbers of people with haemophilia

|                          | Other | Agree | Total |
|--------------------------|-------|-------|-------|
| Associated with <2       | 42 (22%) | 149 (78%) | 191   |
| affected individuals     |       |       |       |
| Associated with 2 +      | 32 (24%) | 104 (76%) | 136   |
| affected individuals     |       |       |       |
| P = 0.74                 |       |       |       |

The support was compared for responders associated with <2 affected individuals compared with those associated with 2 + affected individuals. Numbers and overall percentages are shown. Differences were assessed using chi-square analysis (P-value).
### TABLE 4  Response summaries for responders who did not support the introduction of NGS. Response breakdowns are shown for families and AwH.

| Question                                                                 | All Responders (n = 74) | Families (n = 27) | AwH (n = 47) | F v AwH | P Value |
|-------------------------------------------------------------------------|-------------------------|-------------------|--------------|---------|---------|
| Identifying haemophilia/bleeding disorders at birth would lead to better support and health care for the child and their family | Agree: 44 (59%)          | 15 (56%)          | 29 (62%)     | 0.63    |         |
|                                                                          | Other: 30 (41%)          | 12 (44%)          | 18 (38%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth would extend the life expectancy of a child with a bleeding disorder | Agree: 34 (46%)          | 13 (48%)          | 21 (45%)     | 0.81    |         |
|                                                                          | Other: 40 (54%)          | 14 (52%)          | 26 (55%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth (and not in pregnancy) takes away the parents right to make a decision about whether or not they want to have a child with a bleeding disorder | Agree: 17 (23%)          | 5 (19%)           | 12 (26%)     | 0.57    |         |
|                                                                          | Other: 57 (77%)          | 22 (81%)          | 35 (74%)     |         |         |
| Identifying haemophilia/bleeding disorders before a child develops any symptoms prevents the child and their family from enjoying life whilst they are still symptom-free | Agree: 15 (20%)          | 5 (19%)           | 10 (21%)     | 0.99    |         |
|                                                                          | Other: 59 (80%)          | 22 (81%)          | 37 (79%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth would help research into a cure by enabling more children to be enrolled into clinical trials early on | Agree: 18 (24%)          | 5 (19%)           | 13 (28%)     | 0.41    |         |
|                                                                          | Other: 56 (76%)          | 22 (81%)          | 34 (72%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth would interfere with the early bonding process between parent and child | Agree: 6 (8%)            | 2 (7%)            | 4 (9%)       | 0.99    |         |
|                                                                          | Other: 68 (92%)          | 25 (93%)          | 43 (91%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth would make the diagnosis easier for parents to accept | Agree: 22 (30%)          | 7 (26%)           | 15 (32%)     | 0.79    |         |
|                                                                          | Other: 52 (70%)          | 20 (74%)          | 32 (68%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth would spare parents the difficulties associated with finding a diagnosis for the child later on | Agree: 30 (41%)          | 11 (41%)          | 19 (40%)     | 0.99    |         |
|                                                                          | Other: 44 (59%)          | 16 (59%)          | 28 (60%)     |         |         |
| Even if parents could not know for sure the severity of the haemophilia/bleeding disorder affecting their newborn baby, its still better that they know about the bleeding disorder straight away | Agree: 40 (54%)          | 13 (48%)          | 27 (57%)     | 0.47    |         |
|                                                                          | Other: 34 (46%)          | 14 (52%)          | 20 (43%)     |         |         |
| Identifying haemophilia/bleeding disorders at birth is important as it would enable parents to make informed decisions about future pregnancies | Agree: 39 (53%)          | 16 (59%)          | 23 (49%)     | 0.47    |         |
|                                                                          | Other: 35 (47%)          | 11 (41%)          | 24 (51%)     |         |         |
| It is unethical not to screen newborn babies for conditions that can be treated | Agree: 10 (14%)          | 4 (15%)           | 6 (13%)      | 0.99    |         |
|                                                                          | Other: 64 (86%)          | 23 (85%)          | 41 (87%)     |         |         |

Responses for each question were stratified as “agree” v “other” (other = disagree and neither disagree nor agree).
Differences were assessed using chi-squared analysis (P-value).
Given that participants were being asked about a hypothetical (rather than already implemented) screening programme, it is also possible that participants’ prior knowledge of NGS was limited, a fact that may have skewed their attitudes towards it. However, the current high profile of genomic medicine within the public and policy arena, the fact that all participants had prior experience of a genetic disease in their family as well as the relatively recent introduction (2006) of an NGS in the UK for another genetic condition, Cystic Fibrosis, together meant that participants did not have to make large imaginative leaps to envisage the potential transferability of NGS to haemophilia, and as such, we do not feel that this lack of background knowledge need limit the value of the data.

ACKNOWLEDGEMENTS

The authors would like to gratefully acknowledge the support of the Haemophilia Society UK in facilitating and supporting this study, as well as the affected families and adults who took the time to complete the survey. FB designed the project and contributed to data acquisition, data analysis and interpretation and led in writing the paper. RH contributed to data acquisition as well as analysis and interpretation of data. She also contributed to writing the paper. PY led on the quantitative analysis and contributed to the interpretation of data. He also contributed to writing the paper.

DISCLOSURE

The authors stated that they had no interests which might be perceived as posing a conflict or bias.

ORCID

Felicity K. Boardman https://orcid.org/0000-0002-3268-6276

REFERENCES

1. Nuffield Council on Bioethics. Whole genome sequencing of babies, bioethics briefing note. 2018. http://nuffieldbioethics.org/project/briefing-notes/whole-genome-sequencing-babies. Accessed August 15, 2018.
2. Beales PL, Howard HC. Genomics in newborn screening: Generation Genome: annual report of the chief medical officer. 2016. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/631043/CMO_annual_report_generation_genome.pdf. Accessed August 15, 2018.
3. Taylor-Phillips S, Boardman F, Seedat F, et al. The ethical, social and legal issues with expanding the newborn blood spot test. UK National Screening Committee. 2014.
4. Boemer F, Fasquell C, d’Otreppe S, et al. A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases. Sci Rep. 2011;7:17641.
5. Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia. 2008;14(1):56-64.
6. Balak D, Gouw SC, Plug I, et al. Prenatal diagnosis for haemophilia: a nationwide survey among female carriers in Netherlands. Haemophilia. 2012;18:584-592.
7. Tsai MC, Cheng CN, Wang RJ, Chen KT, Kuo MC, Lin SJ. Cost-effectiveness analysis of carrier and prenatal genetic testing for X-linked hemophilia. J Formos Med Assoc. 2015;114(8):722-728.
8. Beeton K, Neal D, Lee C. An exploration of health-related quality of life in adults with haemophilia—a qualitative perspective. Haemophilia. 2005;11(2):123-132.
9. Beeton K, Neal D, Watson T, Lee CA. Parents of children with haemophilia—a transforming experience. Haemophilia. 2007;13(5):570-579.
10. Wood MF, Hughes SC, Hache LP, et al. Parental attitudes toward newborn screening for Duchenne/Becker muscular dystrophy and spinal muscular atrophy. Muscle Nerve. 2014;49(6):822-828.
11. Tariq B, Ahmed A, Habib A, et al. Assessment of knowledge, attitudes and practices towards newborn screening for congenital hypothyroidism before and after a health education intervention in pregnant women in a hospital setting in Pakistan. Int Health. 2018;10(2):100-107.
12. Boardman F, Young P, Griffiths F. Newborn screening for spinal muscular atrophy: The views of affected families and adults. Am J Hum Genet. 2017;9999:1-16.
13. Potter BK, Avard D, Wilson BJ. Newborn blood spot screening in four countries: stakeholder involvement. J Public Health Policy. 2008;29(1):121-142.
14. Skinner D, Sparkman KL, Bailey DB. Screening for fragile x syndrome: parent attitudes and perspectives. Genet Med. 2003;5(5):378-384.
15. Nuffield Council on Bioethics. Non-invasive prenatal testing: ethical issues. London, UK: Nuffield; 2017.
16. Dankert-Roelse JE, Vernooij-van LA. Newborn screening for cystic fibrosis: Pros and cons. Breathe. 2011;8(1):25-30.
17. Nuffield Council on Bioethics. Genome editing and human reproduction: social and ethical issues. London, UK: Nuffield; 2018.
18. Boardman F, Hale R. I didn’t take it too seriously because I’d just never heard of it: experiential knowledge and genetic screening for thalassaemia in the UK. J Genet Couns. 2019;28(1):141-154.
19. Boardman F, Hale R, Gohel R, Young P. Preventing Lives Affected by Haemophilia: A Mixed Methods Study of the Views of Haemophilic Adults and Their Families Towards Genetic Screening. Mol Genet. Genomic Med. 2019, forthcoming.
20. Lippman A. Prenatal genetic testing and screening: constructing needs and reinforcing inequities. Am J Law Med. 1991;7(1&2):15-52.
21. Boardman F, Young P, Griffiths F. Population screening for Spinal Muscular Atrophy: a mixed methods study. Am J Med Genet A 2016;173(2):421-434.
22. Boardman F, Young P, Warren O, Griffiths F. The role of experiential knowledge within attitudes towards genetic screening: the views of people with and without experience of spinal muscular atrophy. Health Expect. 2017;21(1):201-211.
23. Newcomb P, True B, Walsh J, Dyson M, Lockwood S, Douglas B. Maternal attitudes and knowledge about newborn screening. MCN Am J Matern Child Nurs. 2013;38(5):289-294.

How to cite this article: Boardman FK, Hale R, Young PJ. Newborn screening for haemophilia: The views of families and adults living with haemophilia in the UK. Haemophilia. 2019;25:276–282. https://doi.org/10.1111/hae.13706